National Comprehensive Cancer network (2022) NCCN guidelines; prostate cancer version 4. 2022. In: The category of prostate cancer. https://www.nccn.org/guidelines/category_1. Accessed 10 May 2022
Hatano K, Tohyama N, Kodama T et al (2019) Current status of intensity-modulated radiation therapy for prostate cancer: history, clinical results and future directions. Int J Urol 26(8):775–784. https://doi.org/10.1111/iju.14011
Wang S, Tang W, Luo H et al (2023) The role of image-guided radiotherapy in prostate cancer: a systematic review and meta-analysis. Clin Transl Radiat Oncol 38:81–89. https://doi.org/10.1016/j.ctro.2022.11.001
Article CAS PubMed Google Scholar
Barney BM, Lee RJ, Handrahan D et al (2011) Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys 80(1):301–305. https://doi.org/10.1016/j.ijrobp.2010.06.007
de Crevoisier R, Bayar MA, Pommier P et al (2018) Daily versus weekly prostate cancer image-guided radiotherapy: phase 3 multicenter randomized trial. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2018.07.2006
Zelefsky MJ, Kollmeier M, Cox B et al (2012) Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84(1):125–129. https://doi.org/10.1016/j.ijrobp.2011.11.047
Wilcox SW, Aherne NJ, McLachlan CS et al (2015) Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series. J Med Imaging Radiat Oncol 59(1):125–133. https://doi.org/10.1111/1754-9485.12275
Kok D, Gill S, Bressel M et al (2013) Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol 107(2):140–146. https://doi.org/10.1016/j.radonc.2013.04.007
Valeriani M, Bracci S, Osti MF et al (2013) Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy. Radiat Oncol 8:137. https://doi.org/10.1186/1748-717X-8-137
Article CAS PubMed PubMed Central Google Scholar
Nakamura K, Mizowaki T, Inokuchi H et al (2017) Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance. Int J Clin Oncol. https://doi.org/10.1007/s10147-017-1174-2
Article PubMed PubMed Central Google Scholar
Napieralska A, Majewski W, Kulik R et al (2018) A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients. Radiat Oncol 13(1):235. https://doi.org/10.1186/s13014-018-1171-2
Article CAS PubMed PubMed Central Google Scholar
Zhong Q, Gao H, Li G et al (2014) Significance of image guidance to clinical outcomes for localized prostate cancer. Biomed Res Int 2014:860639. https://doi.org/10.1155/2014/860639
Article PubMed PubMed Central Google Scholar
Kuo YH, Liang JA, Chen GH et al (2021) Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis. Br J Radiol 94(1121):20200456. https://doi.org/10.1259/bjr.20200456
Article PubMed PubMed Central Google Scholar
Jereczek-Fossa BA, Surgo A, Maisonneuve P et al (2019) Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation. Radiol Med 124(1):65–78. https://doi.org/10.1007/s11547-018-0937-9
D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974. https://doi.org/10.1001/jama.280.11.969
Article CAS PubMed Google Scholar
Aizawa R, Takayama K, Nakamura K et al (2020) Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol 25(4):713–719. https://doi.org/10.1007/s10147-019-01596-7
Article CAS PubMed Google Scholar
Uto M, Mizowaki T, Ogura K et al (2017) Volumetric modulated dynamic wavearc therapy reduces the dose to the hippocampus in patients with pituitary adenomas and craniopharyngiomas. Pract Radiat Oncol 7(6):382–387. https://doi.org/10.1016/j.prro.2017.04.004
Mizowaki T, Norihisa Y, Takayama K et al (2016) Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c–T2N0M0 prostate cancer. Int J Clin Oncol 21(4):783–790. https://doi.org/10.1007/s10147-016-0954-4
Article CAS PubMed Google Scholar
Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65(4):965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029
Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244
Article CAS PubMed Google Scholar
Das S, Liu T, Jani AB et al (2014) Comparison of image-guided radiotherapy technologies for prostate cancer. Am J Clin Oncol 37(6):616–623. https://doi.org/10.1097/COC.0b013e31827e4eb9
Morris WJ, Tyldesley S, Rodda S et al (2017) Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):275–285. https://doi.org/10.1016/j.ijrobp.2016.11.026
Ishiyama H, Kamitani N, Kawamura H et al (2017) Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium. Brachytherapy 16(3):503–510. https://doi.org/10.1016/j.brachy.2017.01.006
Nihei K, Nakamura K, Karasawa K et al (2021) A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2021.07.917
Comments (0)